Sergio Coffa

Array ( [id] => 20218647 [patent_doc_number] => 20250281578 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-09-11 [patent_title] => METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY [patent_app_type] => utility [patent_app_number] => 19/217808 [patent_app_country] => US [patent_app_date] => 2025-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28133 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19217808 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20120480 [patent_doc_number] => 20250235511 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-24 [patent_title] => SEMAGLUTIDE IN MEDICAL THERAPY [patent_app_type] => utility [patent_app_number] => 19/174121 [patent_app_country] => US [patent_app_date] => 2025-04-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1404 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -1 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19174121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20007442 [patent_doc_number] => 20250145664 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-05-08 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR IMAGING, DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 19/020677 [patent_app_country] => US [patent_app_date] => 2025-01-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4974 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 141 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19020677 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19875831 [patent_doc_number] => 20250108088 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-04-03 [patent_title] => REGENERATIVE PEPTIDES AND METHODS FOR USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/903801 [patent_app_country] => US [patent_app_date] => 2024-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29820 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18903801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19921729 [patent_doc_number] => 12295988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-13 [patent_title] => Semaglutide in medical therapy [patent_app_type] => utility [patent_app_number] => 18/820792 [patent_app_country] => US [patent_app_date] => 2024-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1299 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18820792 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528172 [patent_doc_number] => 20240352074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => CYCLOPHILIN INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/754189 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19528172 [patent_doc_number] => 20240352074 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-24 [patent_title] => CYCLOPHILIN INHIBITORS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/754189 [patent_app_country] => US [patent_app_date] => 2024-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17232 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754189 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19683999 [patent_doc_number] => 20250002544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => NPY2 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 18/751723 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19683999 [patent_doc_number] => 20250002544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-02 [patent_title] => NPY2 RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 18/751723 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 38 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751723 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19462490 [patent_doc_number] => 20240316159 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => SEMAGLUTIDE IN MEDICAL THERAPY [patent_app_type] => utility [patent_app_number] => 18/736608 [patent_app_country] => US [patent_app_date] => 2024-06-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 27 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18736608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20272004 [patent_doc_number] => 12441773 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-10-14 [patent_title] => Peptides, hydrogel compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/734820 [patent_app_country] => US [patent_app_date] => 2024-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 19 [patent_no_of_words] => 7360 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 102 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18734820 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19717345 [patent_doc_number] => 12202868 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2025-01-21 [patent_title] => Stapled and specifically targeted antimicrobial peptide [patent_app_type] => utility [patent_app_number] => 18/666750 [patent_app_country] => US [patent_app_date] => 2024-05-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 4 [patent_no_of_words] => 5952 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18666750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19432507 [patent_doc_number] => 20240301005 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => NOVEL PEPTIDES [patent_app_type] => utility [patent_app_number] => 18/660504 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 48257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18660504 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19642918 [patent_doc_number] => 20240417438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-12-19 [patent_title] => HUMAN AMYLIN ANALOG POLYPEPTIDES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/661201 [patent_app_country] => US [patent_app_date] => 2024-05-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43465 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18661201 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19430191 [patent_doc_number] => 20240298689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-12 [patent_title] => FASTING CONDITION AS DIETARY TREATMENT OF DIABETES [patent_app_type] => utility [patent_app_number] => 18/657307 [patent_app_country] => US [patent_app_date] => 2024-05-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6933 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 55 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18657307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19556435 [patent_doc_number] => 20240368227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-11-07 [patent_title] => CYCLIC CELL-PENETRATING PEPTIDES WITH ONE OR MORE HYDROPHOBIC RESIDUES [patent_app_type] => utility [patent_app_number] => 18/644750 [patent_app_country] => US [patent_app_date] => 2024-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21506 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18644750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19378525 [patent_doc_number] => 20240268395 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => ANTIFUNGAL PROTEIN COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/639139 [patent_app_country] => US [patent_app_date] => 2024-04-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9702 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18639139 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332606 [patent_doc_number] => 20240247036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => N-Terminal Capping Modules of Ankyrin Repeat Domains [patent_app_type] => utility [patent_app_number] => 18/633283 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18633283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19332606 [patent_doc_number] => 20240247036 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-07-25 [patent_title] => N-Terminal Capping Modules of Ankyrin Repeat Domains [patent_app_type] => utility [patent_app_number] => 18/633283 [patent_app_country] => US [patent_app_date] => 2024-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18633283 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19389410 [patent_doc_number] => 20240279280 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-22 [patent_title] => COMPOUNDS FOR USE AS APELIN RECEPTOR ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 18/627757 [patent_app_country] => US [patent_app_date] => 2024-04-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27684 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18627757 [rel_patent_id] =>[rel_patent_doc_number] =>)